Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
OKYO Pharma Limited Sponsored ADR ( (OKYO) ) has issued an update.
OKYO Pharma announced on February 10, 2026, that it has appointed Flavio Mantelli, MD, PhD, as Chief Medical Officer, adding a prominent ophthalmology specialist with deep expertise in corneal and ocular surface diseases. Mantelli previously led the clinical development, FDA approval and global medical strategy of Oxervate, a corneal disease therapy that reached more than $1 billion in sales in 2024 and is regarded as a benchmark orphan drug success in ophthalmology.
In his new role, Mantelli will direct OKYO’s clinical and regulatory strategy, including advancing urcosimod into planned trials for neuropathic corneal pain and additional orphan indications. The hire, which follows the recent appointment of CEO Robert Dempsey, further strengthens OKYO’s leadership as it prepares a roughly 150-patient Phase 2b/3 study of urcosimod in neuropathic corneal pain, an area with no FDA-approved treatments and high unmet medical need.
The most recent analyst rating on (OKYO) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on OKYO Pharma Limited Sponsored ADR stock, see the OKYO Stock Forecast page.
Spark’s Take on OKYO Stock
According to Spark, TipRanks’ AI Analyst, OKYO is a Neutral.
The score is held down primarily by weak fundamentals (pre-revenue, ongoing losses, negative free cash flow, and negative equity) despite improved 2025 cost and cash-burn trends and zero debt. Technicals are a meaningful offset with strong momentum above key moving averages, while valuation remains challenged due to negative earnings and no indicated dividend yield.
To see Spark’s full report on OKYO stock, click here.
More about OKYO Pharma Limited Sponsored ADR
OKYO Pharma Limited is a clinical-stage biopharmaceutical company listed on the Nasdaq Capital Market that develops innovative therapies for neuropathic corneal pain and inflammatory eye diseases. The company is focused on novel molecules targeting ocular surface conditions, with its flagship candidate, urcosimod, having delivered positive Phase 2 results in neuropathic corneal pain and dry eye disease and slated for a larger Phase 2b/3 trial in neuropathic corneal pain.
Average Trading Volume: 199,861
Technical Sentiment Signal: Sell
Current Market Cap: $72.21M
Learn more about OKYO stock on TipRanks’ Stock Analysis page.